Search

Search Language

English | Use language selector above (below, on mobile) to search additional languages

Open filter

Selected filters
x(Life Sciences & HealthTech)

107 items matching filters

Search Results

Client Result

AI Personalization for Health Plans and Enterprise Health: RadiantGraph Launches With $5 Million Round

2 minute read | November.01.2023

RadiantGraph uses machine learning and artificial intelligence to drive consumer engagement for health plans. It launched after raising $5 million.

Client Result

Kineta Announces $3 Million Registered Direct Offering

2 minute read | October.04.2023

Clinical-stage biotech company Kineta has announced a registered direct offering of more than 890,000 shares of common stock. Orrick advised Kineta.

Client Result

Machine-Learning-Powered Generative Biology: Mirae Asset Group Joins $273M Funding Round for Generate:Biomedicines

2 minute read | September.15.2023

Mirae Asset Global Investments has participated in a $273 million in Series C financing for Generate:Biomedicines.

Client Result

Ferring Pharmaceuticals Enters Royalty Agreement for Bladder Cancer Gene Therapy

2 minute read | August.28.2023

Ferring Pharmaceuticals and Royalty Pharma have entered into a royalty agreement for sales of Ferring’s new gene therapy for bladder cancer.

Client Result

Eli Lilly to Acquire Versanis Bio in up to $1.925 Billion Deal With Potential Implications for Treating Obesity

2 minute read | July.20.2023

Eli Lilly and Company and Versanis Bio have announced a definitive agreement for Lilly to pay up to $1.925 billion in cash to acquire Versanis.

Client Result

Seed Round Will Help Resurrect Bio Protect Crops From Disease

2 minute read | May.17.2023

Resurrect Bio, a biotech startup using gene editing to protect crops from disease, has completed a seed investment round to fuel its growth.

Client Result

Orrick Advises Third Rock Ventures on Investment in CARGO Therapeutics

1 minute read | March.02.2023

The proceeds from the financing will be used to advance CARGO’s autologous CD22 CAR T-cell therapy candidate, CRG-022.

Client Result

Orrick Advises SFJ Pharmaceuticals on Acquisition of Bentracimab Assets from PhaseBio

January.18.2023

Orrick advised SFJ on its acquisition of assets related to the drug Bentracimab from PhaseBio.

Client Result

Orrick Advises Ipsen on Acquisition of Liver Disease Treatment Innovator Albireo

1 minute read | January.09.2023

Orrick is advising Ipsen (Euronext: IPN: ADR: IPSEY) on its acquisition of Albireo Pharma Inc (NASDAQ: ALBO), a leading innovator in bile-acid ...

Client Result

Orrick Advises Catalyst Biosciences in Reverse Merger with GNI Group

1 minute read | December.28.2022

Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. in its acquisition of the F351 program, a ...

Client Result

Orrick Advises BioAtla on $65 Million Underwritten Offering of its Common Stock

1 minute read | November.11.2022

Orrick advised clinical-stage biotech company BioAtla on the sale of 9,745,128 shares of its common stock in an underwritten offering.

Client Result

Orrick Advises Qualifacts on Its Acquisition of OnCall Health

November.03.2022

Congratulations to our client Qualifacts on its acquisition of OnCall Health, a telehealth, patient portal and client engagement technology provider.